Subscribe To
NVRO / Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued
Content Topics
Nevro
Potentially
Better
Than
Traditional
Treatment
Pain
Nevro
Undervalued
Stock
NVRO
NVRO News
By Seeking Alpha
September 1, 2023
Nevro: Economic Realities Too Deep To Ignore, Downgrade To Hold
Nevro Corp. shares have significantly underperformed, selling 57% lower than in 2021. The company's top-line momentum continues, but it faces economic more_horizontal
By Zacks Investment Research
August 15, 2023
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
Nevro's (NVRO) HFX Connect system is expected to treat individual patients per their requirements with 35 pre-programmed customizable plans. more_horizontal
By The Motley Fool
August 2, 2023
Why Shares of Nevro Are Down Wednesday
Nevro said it expects third-quarter revenue to fall between 4% to 6% year over year. The company is reorganizing its sales force. more_horizontal
By Seeking Alpha
August 1, 2023
Nevro Corp. (NVRO) Q2 2023 Earnings Call Transcript
Nevro Corp. (NYSE:NVRO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group LLC Kevin Th more_horizontal
By Zacks Investment Research
August 1, 2023
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.71 more_horizontal
By Zacks Investment Research
June 19, 2023
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
Investors continue to be optimistic about Nevro (NVRO) due to its R&D edge. more_horizontal
By Seeking Alpha
May 9, 2023
Nevro: Potentially Better Than Traditional SCS Treatment For Pain And Undervalued
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficie more_horizontal
By Zacks Investment Research
April 27, 2023
Nevro (NVRO) Q1 Earnings and Revenues Surpass Estimates
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q1, partly owing to robust domestic performance. more_horizontal